Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case

Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case

Abstract Background Patients with advanced salivary gland malignancies (SGCs) have few therapy options. Although results from newly published trials suggest that checkpoint inhibition may be useful in a subgroup of patients, there are no clear criteria for PD-L1 score in SGCs. Chemotherapy benefits...

Full description

Bibliographic Details
Main Authors: Raed Farhat, Noam Asna, Yaniv Avraham, Ashraf Khater, Majd Asakla, Alaa Safia, Sergio Szvalb, Nidal Elkhatib, Shlomo Merchavy
Format: Article
Language:English
Published: Springer 2022-05-01
Series:Discover Oncology
Subjects:
Pembrolizumab
Salivary gland cancers (SGCs): immunotherapy
Complete response (CR)
Online Access:https://doi.org/10.1007/s12672-022-00502-4

Internet

https://doi.org/10.1007/s12672-022-00502-4

Similar Items